scholarly journals AS3MT Polymorphism: A Risk Factor for Epilepsy Susceptibility and Adverse Drug Reactions to Valproic Acid and Oxcarbazepine Treatment in Children From South China

2021 ◽  
Vol 15 ◽  
Author(s):  
Xiaomei Fan ◽  
Yuna Chen ◽  
Jieluan Lu ◽  
Wenzhou Li ◽  
Xi Li ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Adverse Drug Reactions ◽  
South China ◽  
Target Genes ◽  
Pediatric Epilepsy ◽  
Drug Reactions ◽  
Intractable Seizures ◽  
Genotypic Analysis ◽  
Epileptic Children ◽  
Chinese Cohort

Epilepsy is a common neurologic disorder characterized by intractable seizures, involving genetic factors. There is a need to develop reliable genetic markers to predict the risk of epilepsy and design effective therapies. Arsenite methyltransferase (AS3MT) catalyzes the biomethylation of arsenic and hence regulates arsenic metabolism. AS3MT variation has been linked to the progression of various diseases including schizophrenia and attention deficit or hyperactivity disorder. Whether genetic polymorphism of AS3MT contributes to epilepsy remains unclear. In this study, we investigated the association of AS3MT gene polymorphism with susceptibility to epilepsy in children from south China. We also explored the effect of AS3MT variation on the safety of antiepileptic drugs. Genotypic analysis for AS3MT rs7085104 was performed using samples from a Chinese cohort of 200 epileptic children and 244 healthy individuals. The results revealed a genetic association of AS3MT rs7085104 with susceptibility to pediatric epilepsy. Mutant homozygous GG genotype exhibited a lower susceptibility to childhood epilepsy than AA genotype. Carriers of AS3MT rs7085104 AA genotype exhibited a higher risk of digestive adverse drug reactions (dADRs) in children when treated with valproic acid (VPA) or oxcarbazepine (OXC). Additionally, bioinformatics analysis identified eight AS3MT target genes related to epilepsy and three AS3MT-associated genes in VPA-related dADRs. The effects of AS3MT on epilepsy might involve multiple targets including CNNM2, CACNB2, TRIM26, MTHFR, GSTM1, CYP17A1, NT5C2, and YBX3. This study reveals that AS3MT may be a new gene contributing to epileptogenesis. Hence, analysis of AS3MT polymorphisms will help to evaluate susceptibility to pediatric epilepsy and drug safety.

Seizure and Toxic Epidermal Necrolysis with Fluoroquinolone; Another Case of TEN with Levofloxacin; Neurotoxicity with Unexpected High Levels of Free Valproic Acid; Acute Clonidine Withdrawal Leads to an Acute Myocardial Infarction; Hepatotoxicity and Hepatorenal Toxicity with SSRIs; Serotonin Toxicity Associated with Linezolid; The RADAR Project – Research on Adverse Drug Events and Reports; Nonadherence Causes Problems!

2005 ◽  
Vol 40 (8) ◽  
pp. 650-657 ◽  
Author(s):  
Joel Shuster
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Valproic Acid ◽  
Toxic Epidermal Necrolysis ◽  
Adverse Drug Reactions ◽  
Adverse Drug Events ◽  
Drug Reactions ◽  
Clonidine Withdrawal ◽  
Serotonin Toxicity

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

Adverse drug reactions induced by valproic acid

2013 ◽  
Vol 46 (15) ◽  
pp. 1323-1338 ◽  
Author(s):  
Radu M. Nanau ◽  
Manuela G. Neuman
Keyword(s):  
Valproic Acid ◽  
Adverse Drug Reactions ◽  
Drug Reactions

Pharmacogenetics of valproic acid as unmodified risk factor of adverse drug reactions

2011 ◽  
Vol 7 ◽  
pp. 26-38 ◽  
Author(s):  
Natalia Shnayder ◽  
Marina Pilugina ◽  
Diana Dmitrenko ◽  
Elena Bochanova ◽  
Evgenia Shapovalova ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Risk Factor ◽  
Adverse Drug Reactions ◽  
Drug Reactions

scholarly journals ISMP Adverse Drug Reactions: Adalimumab-Induced Aseptic Meningitis Pill Desiccant -Induced Acute Hypoxic Respiratory Failure Rivastigmine Patch -Induced Angioedema Acute Liver Failure Due to Etodolac Severe Cognitive Impairment Due to High Free Valproic Acid Levels

2018 ◽  
Vol 53 (5) ◽  
pp. 292-295
Author(s):  
Michael A. Mancano ◽  
Kristen J. Milenki ◽  
Morgan V. Esordi ◽  
Darshil D. Patel
Keyword(s):  
Valproic Acid ◽  
Cognitive Impairment ◽  
Adverse Drug Reactions ◽  
Drug Reactions ◽  
Safe Medication ◽  
Rivastigmine Patch ◽  
Temple University ◽  
The Us ◽  
Hypoxic Respiratory Failure ◽  
E Mail

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of revention, and promote reporting of ADRs to the US Food and Drug Administration’s (FDA) MedWatch program (800-ßDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with ur readers. E-mail [email protected] ). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA’s MedWatch program and Temple University School of Pharmacy. ISMP is an FDA MedWatch partner.

scholarly journals Genetic Variations ofABCC2Gene Associated with Adverse Drug Reactions to Valproic Acid in Korean Epileptic Patients

2013 ◽  
Vol 11 (4) ◽  
pp. 254 ◽  
Author(s):  
Ji Hyun Yi ◽  
Yang-Je Cho ◽  
Won-Joo Kim ◽  
Min Goo Lee ◽  
Ji Hyun Lee
Keyword(s):  
Valproic Acid ◽  
Adverse Drug Reactions ◽  
Genetic Variations ◽  
Drug Reactions ◽  
Epileptic Patients

scholarly journals Rivaroxaban-Induced DRESS; Serotonin Syndrome Induced by Paliperidone; Piperacillin-Tazobactam–Induced Nephritis and Hepatitis; Brentuximab-Induced Hand-Foot Syndrome; Valproic Acid–Induced Hyperkalemia

2017 ◽  
Vol 52 (2) ◽  
pp. 94-97
Author(s):  
Michael A. Mancano
Keyword(s):  
Valproic Acid ◽  
Adverse Drug Reactions ◽  
Serotonin Syndrome ◽  
Drug Reactions ◽  
The Us ◽  
Hand Foot Syndrome

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers.

Sign in / Sign up

Export Citation Format

Share Document